Hong Kong Stock Movement | Innovent Biologics (01801) Rises Nearly 3% as IBI3003 Receives FDA Fast Track Designation for Multiple Myeloma Treatment

Stock News01-28

Innovent Biologics (01801) saw its shares climb nearly 3%, reaching an increase of 2.2% to HK$83.6 by the time of writing, with a trading volume of HK$204 million. According to an announcement on the company's official WeChat account dated January 27, 2026, its anti-GPRC5D/BCMA/CD3 trispecific antibody, IBI3003, has been granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA). The intended indication is for the treatment of relapsed or refractory multiple myeloma (R/R MM) in patients who have received at least four prior lines of therapy, including a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38 monoclonal antibody. IBI3003 was developed using Innovent Biologics' proprietary Sanbody® platform and is currently undergoing Phase I/II clinical studies in China, Australia, and the United States (initiation imminent) to evaluate its efficacy and safety in R/R MM.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1128000326?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-28 10:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1128000326","market":"fut","top_or_hot":-1,"title":"Hong Kong Stock Movement | Innovent Biologics (01801) Rises Nearly 3% as IBI3003 Receives FDA Fast Track Designation for Multiple Myeloma Treatment","media":"Stock News","content":"<p>Innovent Biologics (01801) saw its shares climb nearly 3%, reaching an increase of 2.2% to HK$83.6 by the time of writing, with a trading volume of HK$204 million.\nAccording to an announcement on the company's official WeChat account dated January 27, 2026, its anti-GPRC5D/BCMA/CD3 trispecific antibody, IBI3003, has been granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA).\nThe intended indication is for the treatment of relapsed or refractory multiple myeloma (R/R MM) in patients who have received at least four prior lines of therapy, including a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38 monoclonal antibody.\nIBI3003 was developed using Innovent Biologics' proprietary Sanbody® platform and is currently undergoing Phase I/II clinical studies in China, Australia, and the United States (initiation imminent) to evaluate its efficacy and safety in R/R MM.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hong Kong Stock Movement | Innovent Biologics (01801) Rises Nearly 3% as IBI3003 Receives FDA Fast Track Designation for Multiple Myeloma Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHong Kong Stock Movement | Innovent Biologics (01801) Rises Nearly 3% as IBI3003 Receives FDA Fast Track Designation for Multiple Myeloma Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-01-28 10:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Innovent Biologics (01801) saw its shares climb nearly 3%, reaching an increase of 2.2% to HK$83.6 by the time of writing, with a trading volume of HK$204 million.\nAccording to an announcement on the company's official WeChat account dated January 27, 2026, its anti-GPRC5D/BCMA/CD3 trispecific antibody, IBI3003, has been granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA).\nThe intended indication is for the treatment of relapsed or refractory multiple myeloma (R/R MM) in patients who have received at least four prior lines of therapy, including a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38 monoclonal antibody.\nIBI3003 was developed using Innovent Biologics' proprietary Sanbody® platform and is currently undergoing Phase I/II clinical studies in China, Australia, and the United States (initiation imminent) to evaluate its efficacy and safety in R/R MM.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2097828714.EUR","symbol_name":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","start_time":0,"source_url":"","article_id":"1128000326","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1128000326","pubTimestamp":1769566699,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Innovent Biologics (01801) saw its shares climb nearly 3%, reaching an increase of 2.2% to HK$83.6 by the time of writing, with a trading volume of HK$204 million. According to an announcement on the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","BK1161":"生物科技","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","LU0455707207.USD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (USD) INC","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU2242644610.SGD":"Fidelity China Innovation A-ACC-SGD","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","BK1583":"高瓴概念","LU0502904849.HKD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (HKD) ACC","01801":"信达生物","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","BK1589":"北水核心资产","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币"},"translate_title":"港股动向|信达生物(01801)涨近3%IBI3003获FDA多发性骨髓瘤治疗快速通道认定","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01801":1},"content_text":"Innovent Biologics (01801) saw its shares climb nearly 3%, reaching an increase of 2.2% to HK$83.6 by the time of writing, with a trading volume of HK$204 million.\nAccording to an announcement on the company's official WeChat account dated January 27, 2026, its anti-GPRC5D/BCMA/CD3 trispecific antibody, IBI3003, has been granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA).\nThe intended indication is for the treatment of relapsed or refractory multiple myeloma (R/R MM) in patients who have received at least four prior lines of therapy, including a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38 monoclonal antibody.\nIBI3003 was developed using Innovent Biologics' proprietary Sanbody® platform and is currently undergoing Phase I/II clinical studies in China, Australia, and the United States (initiation imminent) to evaluate its efficacy and safety in R/R MM.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1128000326","isCrawlerRequest":true}